Clinical Research · Updated May 2026

FLOW Trial: Renal Outcomes with Semaglutide

Perkovic et al., NEJM 2024. n=3,533 adults with T2D and CKD. 24% reduction in major kidney disease events. PMID 38785307.

Dr. Parmis - Medical Researcher
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Adam Kennah, M.D.
Board-Certified Physician
Last clinically reviewed: April 28, 2026 · This page is informational and does not constitute medical advice.

Summary

Perkovic et al., NEJM 2024. n=3,533 adults with T2D and CKD. 24% reduction in major kidney disease events. PMID 38785307.

Source hierarchy

Related clinical pages

Note for patients: Clinical trial data on this site is summarized for general education. Specific dosing decisions, contraindication assessments, and treatment plans must be made with a licensed healthcare provider who has reviewed your full medical history.